Merck invests $1 billion in the U.S

Article Excerpt

MERCK & CO. INC., $73.47, is a buy. The drugmaker (New York symbol MRK; TSINetwork Rating: Above Average) (www.merck.com; Shares outstanding: 2.5 billion; Market cap: $192.4 billion; Dividend yield: 4.4%), will now expand its U.S. manufacturing footprint with a $1 billion plant in Delaware. The facility’s products will include biologic drugs and a new, easier-to-use version of Keytruda, the company’s blockbuster cancer drug. Merck’s biggest exposure to the Trump administration’s tariffs is Keytruda, which is the world’s top-selling pharmaceutical, and is approved for treating lung cancer, melanoma and other tumours. Keytruda accounts for roughly half of the company’s revenue. Merck & Co. is a buy. buy…